According to Nxera Pharma's latest financial reports the company has S$0.43 Billion in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | S$0.46 B | -32.15% |
2022-12-31 | S$0.68 B | -3.55% |
2021-12-31 | S$0.70 B | 37.74% |
2020-12-31 | S$0.51 B | 169.59% |
2019-12-31 | S$0.19 B | |
2018-03-31 | S$0.34 B | 100.64% |
2017-03-31 | S$0.17 B | 43.52% |
2016-03-31 | S$0.12 B | 89.49% |
2015-03-31 | S$63.88 M | -27.65% |
2014-03-31 | S$88.3 M | 164.47% |
2013-03-31 | S$33.38 M | 47.02% |
2012-03-31 | S$22.71 M | -14.5% |
2011-03-31 | S$26.56 M | -4.45% |
2010-03-31 | S$27.79 M | 2.24% |
2009-03-31 | S$27.18 M | -59.86% |
2008-03-31 | S$67.73 M | -41.29% |
2007-03-31 | S$0.11 B | -11.09% |
2006-03-31 | S$0.12 B | -13.12% |
2005-03-31 | S$0.14 B |